EcoDrugPlus

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSODEG00000018913
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSODEG00000013820
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSODEG00000004088
Gene Symbol: CHRNA4
1 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSODEG00000013998
Gene Symbol: CHRNA7
2 Cross references
243 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSODEG00000011916
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSODEG00000014380
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSODEG00000001705
Gene Symbol: CMA1
3 Cross references
292 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSODEG00000016157
Gene Symbol: F2
3 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSODEG00000004515
Gene Symbol: F3
1 Cross references
243 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSODEG00000008696
Gene Symbol: F10
1 Cross references
237 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSODEG00000006089
Gene Symbol: F11
1 Cross references
216 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSODEG00000007843
Gene Symbol: F12
3 Cross references
185 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).